The FATP2 axis in cancer: Structural informatics and implications for drug discovery [0.03%]
癌症中的FATP2轴：结构信息学及其对药物发现的影响
Yuanyuan Wang,Yunjiao Zhang,Bo Zhang et al.
Yuanyuan Wang et al.
Dysregulated fatty acid (FA) metabolism sustains tumour growth and metastasis, yet effective therapeutic interventions remain elusive. Fatty acid transport protein 2 (FATP2/SLC27A2) has emerged as a pivotal metabolic gatekeeper, coordinatin...
Physics-inspired explainable AI for mechanistic and decision support in drug discovery [0.03%]
物理启发的可解释人工智能在药物发现中的机制和决策支持
Antonio Lavecchia
Antonio Lavecchia
Explainable artificial intelligence (XAI) is increasingly recognized as essential for trustworthy drug discovery, yet many approaches remain post hoc and correlational. This review examines physics-inspired XAI as a framework for improving ...
Usefulness of the sulfonamide motif in medicinal chemistry: exploring the pharmacological landscape of FDA-approved and investigational sulfonamide drugs [0.03%]
磺胺类药物在医学化学中的作用：探索美国食品药品监督管理局已批准和正在研究的磺胺类药物的药理景观
Sébastien Sueron,Alban Vigroux,François-Hugues Porée
Sébastien Sueron
The sulfonamide motif is widely used in the design of small molecules owing to its enzymatic stability but also its potentiality to improve target engagement and to provide a beneficial ADME profile. From the commercialization of Prontosil...
Accelerating the orphan GPCR pipeline: GPR149 as a case study in dual-domain target validation [0.03%]
加速孤儿G蛋白偶联受体(GPCR)的管线：以GPR149为例的双重结构域靶点验证研究
Michael A S Guth
Michael A S Guth
High failure rates in drug development for central nervous system (CNS) and metabolic diseases frequently stem from a lack of knowledge about their selected drug targets. With unknown ligand chemistry, orphan G-protein-coupled receptors (GP...
New perspectives for better R&D performance: lessons learned from leading pharma companies [0.03%]
研发新视角：领先药企的经验教训
Alexander Schuhmacher,Oliver Gassmann,Sara Knapp et al.
Alexander Schuhmacher et al.
The research and development (R&D) productivity of pharmaceutical companies has been widely studied and analyzed for many years in both academia and industry, and pharmaceutical companies have launched various initiatives to improve their R...
National differences in drug discovery and the role of startups: Insights from cross-national analysis of Phase III candidates [0.03%]
国家间药物发现的差异及初创企业的作用——来自III期候选药物跨国分析的启示
Ryo Okuyama
Ryo Okuyama
Startups are integral to new drug discovery, with a strong association between a country's global share and the contribution of young small- and medium-sized enterprises (SMEs) to drug candidate discovery. However, cross-national difference...
Yaru Liu,Yali Song,Youzhi Wang et al.
Yaru Liu et al.
Sphingosine-1-phosphate (S1P), a downstream metabolite of the sphingolipid pathway, exerts diverse biological functions, is implicated in a wide spectrum of diseases, and has been shown to have central roles in regulating cell proliferation...
Decentralised clinical trials of investigational medicinal products [0.03%]
去中心化临床试验开展要点思考——基于 investigational medicinal products 的实践反思
Abdel Douiri,Mohammad Alhnan,Muhammad Rizwan Asghar et al.
Abdel Douiri et al.
Decentralised clinical trials (DCTs) can gather objective data in real-world settings through digital health technologies (DHTs) to obtain real-time measurements of clinical outcomes. However, such measurements remain infrequent in clinical...
Medicinal chemistry strategies to breach the blood-brain barrier: structural design principles for brain-targeted therapeutics [0.03%]
药物化学策略打破血脑屏障的结构设计原理：针对大脑治疗的药物合成原则
Harikesh Kumar Gupta,Jatin Jangra,Vishwakarma Krishna Ramesh et al.
Harikesh Kumar Gupta et al.
The blood-brain barrier (BBB) remains a critical limitation in central nervous system (CNS) drug development, restricting brain exposure to most therapeutics. Despite advances in macromolecular delivery, small molecules continue to predomin...
Evolution of the division of labor for First-in-Class Drugs: A Quantitative Analysis of Trends across Company Types, Modalities, and Therapeutic Areas (2012-2024) [0.03%]
首款药物分工的演变：对公司类型、模式和治疗领域的趋势进行定量分析（2012-2024）
Yusuke Izumiya,Yoshiyuki Kobayashi,Itsuki Kageyama et al.
Yusuke Izumiya et al.
The pharmaceutical industry is transitioning toward diverse modalities, a shift that fundamentally reshapes the division of labor within R&D. Analysis of 260 first-in-class drugs approved by the United States Food and Drug Administration (F...